SEATTLE, Wash. and VANCOUVER, British Columbia, Jan. 27, 2023 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued an inducement grant of stock options to a new employee. Achieve’s Board of…
/Read More
Topline Results Remain on Schedule to be Reported in the Second Quarter of 2023 SEATTLE, Wash. and VANCOUVER, British Columbia, January 9, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the final…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, December 21, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,459,328 covering the mesylate…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, November 15, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into definitive agreements for a private placement of its securities for gross proceeds…
/Read More
Company to host conference call at 4:30 PM EST today, November 14, 2022 SEATTLE, WA and VANCOUVER, British Columbia, November 14, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced third quarter…
/Read More